TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30972436

Group type: EXPERIMENTAL
Intervention: Beta-thalassaemia major patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Beta-thalassaemia major patients with significant myocardial iron overload
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study: 28985425

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 96
Study: 25377629

Group type: EXPERIMENTAL
Intervention: Real-time, focused educational interventions by physician peers in addition to usual training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 44
Study: 21546277

Group type: EXPERIMENTAL
Intervention: Limited bowel preparation (BP) method: liberal use of liquid diet, sodium phosphate laxative, and self-administered enema the day before surgery.
Number of subjects: 112

Group type: COMPARATOR
Intervention: 3-day conventional bowel preparation (BP) method: diet restriction, oral antibiotics, oral laxatives, and saline enemas over a 3-day period.
Number of subjects: 112
Study: 22111945

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA)
Number of subjects: 40
Study: 19922311

Group type: EXPERIMENTAL
Intervention: PVP combined with 125I seed implantation
Number of subjects: 80

Group type: COMPARATOR
Intervention: PVP alone
Number of subjects: 80
Study: 16859579

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 1: 4 MIU/m2 per day, every other week for 24 weeks (n = 10)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 2: 8 MIU/m2 per day, every other week for 24 weeks (n = 9)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 3: 4 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 11)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 4: 8 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 10)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall efficacy of IL-2 treatment
Number of subjects: 41
Study: 12560953

Group type: EXPERIMENTAL
Intervention: Tandem bicycle
Number of subjects: 7

Group type: COMPARATOR
Intervention: Chair apparatus
Number of subjects: 7
Study: 10986302

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Parenteral Gold (GST)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cox proportional hazards test for all withdrawals
Number of subjects: 159

Group type: COMPARATOR
Intervention: Observational studies vs RCTs
Number of subjects: 159
Study: 9312310

Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg) after food
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bicalutamide (50 mg) after fasting
Number of subjects: 15
Study: 8379864

Group type: EXPERIMENTAL
Intervention: Abdominal nerve blockade with 0.5% bupivacaine with adrenaline and xylocaine 1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no abdominal nerve blockade)
Number of subjects: 30
Study: 3665121

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 16
Study: 30930587

Group type: EXPERIMENTAL
Intervention: Cervical Traction (CT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transverse Oscillatory Pressure (TOP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (Cnt)
Number of subjects: 75
Study: 29098249

Group type: EXPERIMENTAL
Intervention: Free dental filling intervention (oral health examination and free filling of shallow and moderate caries once a year for 3 years)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Oral health examination only (once a year)
Number of subjects: 918
Study: 26251005

Group type: EXPERIMENTAL
Intervention: Tai Chi program
Number of subjects: 266
Study: 23437905

Group type: EXPERIMENTAL
Intervention: Oral health education and training (lecture and hands-on training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Facilitated group discussion (control)
Number of subjects: 30
Study: 20331370

Group type: EXPERIMENTAL
Intervention: Acapella
Number of subjects: 23

Group type: COMPARATOR
Intervention: PEP mask
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 23
Study: 18779677

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 16644897

Group type: EXPERIMENTAL
Intervention: Minimal postal intervention (general information letter and questionnaire)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Minimal postal intervention
Number of subjects: 990
Study: 12525442

Group type: EXPERIMENTAL
Intervention: 2 or 5 mg mifepristone per day for 120 days
Number of subjects: 90
Study: 10805319

Group type: EXPERIMENTAL
Intervention: CGP 60536
Number of subjects: 0
Study: 8877932

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg tid
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg bid
Number of subjects: 135

Group type: COMPARATOR
Intervention: Diclofenac 50 mg tid
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg tid (follow-up)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg bid (follow-up)
Number of subjects: 135
Study: 1642079

Group type: EXPERIMENTAL
Intervention: Intermediate-acting insulin twice daily (2-dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Preprandial regular insulin and intermediate-acting insulin at bedtime (4-dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (before insulin treatment)
Number of subjects: 10
Study: 6673724

Group type: EXPERIMENTAL
Intervention: Salbutamol powder (400 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terbutaline aerosol (500 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 10
Study: 30883357

Group type: EXPERIMENTAL
Intervention: Adapted Argentine Tango intervention (12 weeks, 20 lessons)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-contact control group (N=10)
Number of subjects: 30
Study: 30532278

Group type: EXPERIMENTAL
Intervention: Electric breast pump
Number of subjects: 30
Study: 26830414

Group type: EXPERIMENTAL
Intervention: PLAY Project plus Community Standard (CS) Treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Community Standard (CS) Treatment
Number of subjects: 112
Study: 24249320

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HCT) with myeloablative conditioning in 36 patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HCT) with reduced-intensity conditioning (RIC) in 24 patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GvHD) prophylaxis with methotrexate and cyclosporine A in 36 patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GvHD) prophylaxis with cyclosporine A plus mycophenolate mofetil in 24 patients
Number of subjects: 60
Study: 22313548

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor (H-GPI)
Number of subjects: 100
Study: 19804591

Group type: EXPERIMENTAL
Intervention: Skin protection regimen (skin care + skin protection)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Skin protection alone
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no recommendation)
Number of subjects: 800
Study: 16936707

Group type: EXPERIMENTAL
Intervention: Intranasal insulin aspart (ASP‐I) 40 IU acute and 4 x 40 IU/day over 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal regular human insulin (RH‐I) 40 IU acute and 4 x 40 IU/day over 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16281077

Group type: EXPERIMENTAL
Intervention: AML-80
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: AML-83
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: AML-87
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: AML-91
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: AML-97
Number of subjects: 251
Study: 12131215

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Protease inhibitors (PI)
Number of subjects: 34
Study: 10213008

Group type: EXPERIMENTAL
Intervention: Irinotecan (Campto)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose 5-fluorouracil (5-FU) infusion
Number of subjects: 0
Study: 7631635

Group type: EXPERIMENTAL
Intervention: HIV seroprevalence among women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV seroprevalence among men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of male patients reporting vaginal intercourse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of male patients reporting receptive oral sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of male patients always using condoms for anal sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of male patients always using condoms for vaginal sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of male patients always using condoms for oral sex
Number of subjects: 0
Study: 2190850

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times a day for 8 or 16 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7010854

Group type: COMPARATOR
Intervention: 200 mg of metoprolol plus placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 200 mg of metoprolol plus 25 mg of hydrochlorothiazide
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 200 mg of metoprolol plus 50 mg hydrochlorothiazide
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol plus 50 mg of hydralazine
Number of subjects: 119
Study: 31390500

Group type: EXPERIMENTAL
Intervention: Volanesorsen
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27198535

Group type: EXPERIMENTAL
Intervention: Family Eats web‐based intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study: 25814051

Group type: EXPERIMENTAL
Intervention: Sport students (SLS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dental students (ZMS)
Number of subjects: 114
Study: 23484100

Group type: EXPERIMENTAL
Intervention: Fosteum (27 mg natural genistein, 200 IU cholecalciferol, 20 mg citrated zinc bisglycinate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Squadrito formulation (27 mg natural genistein, 400 IU cholecalciferol, 500 mg elemental calcium)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Citracal Plus Bone Density Builder (27 mg synthetic genistein, 600 mg elemental calcium, 400 IU vitamin D3, 50 mg magnesium, 7.5 mg zinc, 1 mg copper, 75 μg molybdenum, 250 μg boron)
Number of subjects: 30
Study: 19892506

Group type: EXPERIMENTAL
Intervention: Computer-based lectures
Number of subjects: 44

Group type: COMPARATOR
Intervention: Classroom lectures
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Computer-based lectures (in residents without prior training)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Classroom lectures (in residents without prior training)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Computer-based lectures (in residents with prior training)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Classroom lectures (in residents with prior training)
Number of subjects: 44
Study: 19850257

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 477
Study: 17010305

Group type: EXPERIMENTAL
Intervention: Left alone (boredom)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Solving maths problems (frustration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reprimanded for nail biting (contingent attention)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous conversation (noncontingent attention)
Number of subjects: 40
Study: 15006845

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide (4 mg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 11342699

Group type: EXPERIMENTAL
Intervention: Dual-release formulation of L-dopa plus benserazide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Slow-release formulation of L-dopa plus benserazide
Number of subjects: 16
Study: 9040213

Group type: EXPERIMENTAL
Intervention: Diet plus calcium (1.0 g/day) and vitamin D (32,000 IU/wk) supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diet plus calcium and vitamin D supplementation
Number of subjects: 14
Study: 7713100

Group type: EXPERIMENTAL
Intervention: Quinapril 2.5 mg b.i.d.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quinapril 5 mg b.i.d.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg b.i.d.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg.day-1
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2455118

Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg p.o.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 29329042

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4g/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 27035372

Group type: EXPERIMENTAL
Intervention: Psychotherapy for depression (3 months duration)
Number of subjects: 217
Study: 24901821

Group type: EXPERIMENTAL
Intervention: VX-222 + telaprevir (DUAL regimen; n=47)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: VX-222 + telaprevir + ribavirin (TRIPLE regimen; n=46)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: VX-222 + peginterferon + ribavirin (QUAD regimen; n=59)
Number of subjects: 152
Study: 22902522

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 16
Study: 20059568

Group type: EXPERIMENTAL
Intervention: Four quarterly bonus checks
Number of subjects: 179

Group type: COMPARATOR
Intervention: Single year-end bonus (maximum of U.S.$5,000/year)
Number of subjects: 179
Study: 18708832

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (2 liters/minute)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control (no supplemental oxygen)
Number of subjects: 389
Study: 16820403

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14563968

Group type: EXPERIMENTAL
Intervention: Adjunct abciximab therapy (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adjunct abciximab therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard antithrombotic therapy (aspirin, clopidogrel, and heparin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both abciximab and filter protection
Number of subjects: 50
Study: 10891434

Group type: EXPERIMENTAL
Intervention: Filgrastim (10 microg/kg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8882027

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1546139

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg t.i.d.)
Number of subjects: 0
Study: 4074610

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study: 29676440

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2/dose)
Number of subjects: 25
Study: 27562403

Group type: EXPERIMENTAL
Intervention: LPS (lipopolysaccharide)
Number of subjects: 16
Study: 24292896

Group type: EXPERIMENTAL
Intervention: In-person delivery of genomic risk results from a genetic counselor
Number of subjects: 300

Group type: COMPARATOR
Intervention: Online delivery of genomic risk results through the testing company's website
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall preference for receiving results online
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Trust levels among participants with increased genetic risk
Number of subjects: 300
Study: 21750974

Group type: EXPERIMENTAL
Intervention: CHO gel ingestion
Number of subjects: 11
Study: 20733443

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol
Number of subjects: 231

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 231
Study: 19116007

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural rehabilitation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 125
Study: 16026367

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.045 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.225 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.45 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.75 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Metformin 1000 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Liraglutide (all doses)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 210

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 210
Study: 12450642

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg orally)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10579141

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ketoconazole and Itraconazole
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rifampin, Carbamazepine, and Phenytoin
Number of subjects: 59
Study: 8600189

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Exercise + HRT
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study: 1725914

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Not specified (patients without ischemia)
Number of subjects: 298
Study: 6352659

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combination of cephalothin, carbenicillin and gentamicin
Number of subjects: 48
Study: 31302943

Group type: EXPERIMENTAL
Intervention: Oral Tranexamic Acid (TA) 1,500 mg daily for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29869380

Group type: EXPERIMENTAL
Intervention: BMW guidewire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot 50 guidewire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressure ≤12 atm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressure >12 atm
Number of subjects: 0
Study: 27083496

Group type: EXPERIMENTAL
Intervention: MeDiet-nuts
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: MeDiet-EVOO
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control
Number of subjects: 520
Study: 24898236

Group type: EXPERIMENTAL
Intervention: Breakfast group
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: No Breakfast (NB) group
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 309
Study: 22621626

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg daily
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 20150175

Group type: EXPERIMENTAL
Intervention: Magnetic-activated cell sorting (MACS) for sperm preparation (D + M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional density gradient centrifugation (DGC)
Number of subjects: 60
Study: 17367362

Group type: EXPERIMENTAL
Intervention: J-shaped active fixation (AF) leads
Number of subjects: 200

Group type: COMPARATOR
Intervention: J-shaped passive fixation (PF) leads
Number of subjects: 200
Study: 15465628

Group type: EXPERIMENTAL
Intervention: Pre-treatment with guanine nucleotides (GTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endogenous GAL
Number of subjects: 0
Study: 11595248

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Health education control (CTL)
Number of subjects: 35
Study: 9637638

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil at a dosage of 0.1 microg kg(‐1) x min(‐1) until skin closure
Number of subjects: 19
Study: 7986280

Group type: EXPERIMENTAL
Intervention: Ethyl alcohol 0.55‐0.66 g/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blood alcohol levels > 100 mg/100 ml
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study: 2904218

Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine plus 50 mg pirenzepine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine plus 50 mg pirenzepine
Number of subjects: 16
Study: 31057137

Group type: EXPERIMENTAL
Intervention: Self-check-in kiosk
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nurse-initiated patient identification
Number of subjects: 100
Study: 28291572

Group type: EXPERIMENTAL
Intervention: Atomoxetine 60mg
Number of subjects: 19
Study: 25925842

Group type: EXPERIMENTAL
Intervention: edoxaban 15 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: edoxaban 30 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: edoxaban 60 mg once daily
Number of subjects: 50